ArticleMetabolomics : Official journal of the Metabolomic Society2026
Pre-diagnostic metabolites in peripheral blood of Langerhans cell histiocytosis children with posterior pituitary involvement.
Article in Metabolomics : Official journal of the Metabolomic Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundLangerhans cell histiocytosis (LCH) is an inflammatory and neoplastic disorder. The levels of metabolites in the plasma of children with LCH have not been studied and may be related to disease progression.
objectivesWe committed to find novel pre-diagnostic metabolites in the plasma of LCH children with posterior pituitary involvement (PI).
methodsNon-targeted metabolomics sequencing was used to detect specific and pre-diagnostic metabolites in the plasma of children with LCH. Plasma samples from 56 children with LCH and 27 healthy volunteers were enrolled. Plasma samples of children with LCH were divided into three groups: children have no PI or central nervous system-risk (CNS-risk) bone lesions (NPC group), children with CNS-risk bone lesions but without PI (CNS-risk group), and children with PI (PI group).
resultsThe N-acetylneuraminic acid, lipoamide, L-Glutathione oxidized and indole-3-propionic acids were potential pre-diagnostic metabolites for LCH children with PI in comparison with the healthy volunteers. Metabolites in the plasma of LCH children with PI enriched specific signaling pathways including arachidonic acid metabolism, ferroptosis, etc. Through targeted metabolomics sequencing, we verified that specific metabolites were existed in the stratified involvements of patients with LCH, such as N-acetylneuraminic acid and Vitamin A, which may be related with alteration of blood-brain barrier permeability and LCH disease progression. Through the joint multi-omics analyses, we discovered that the peripheral dendritic cells may have ferroptosis phenomena, which was regulated by osteopontin secreted in the plasma of patients with LCH.
conclusionAnalyses and identification the differential metabolites in the plasma of children with LCH may significantly improve the early diagnosis and stratified treatment of children with pituitary invovlement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.